What is VRTX's five-year median P/E?

28.1x. Half of VRTX's weekly readings over the last five years were higher and half were lower. This page has 820 weekly readings, from Feb 14, 2011 to Oct 26, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares VRTX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Vertex Pharmaceuticals (VRTX) valuation

Health Care

$529.69

Latest weekly close · Market cap $135.2B

Above its usual range

Vertex Pharmaceuticals' P/E of 30.9x is higher than 83% of its weekly readings over the last five years (as of Oct 29, 2026).

Forward P/E 25.7× (analyst estimates, not ranked).

Weekly P/E with its 5-year range

P/E each weekMiddle half of the last 5 years5-year median 28.1×

5-year median: 28.1×
10-year median: 28.6×
5-year low to high: 22.0× to 33.6×
Versus 5-year median: +10%

P/E

83rdpercentile

of its weekly readings over the last five years

Growth, last 12 months vs the year before

Revenue: +10%accelerating
EPS: +22%

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

P/E at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

VRTX P/E at each year-end
Year-end	P/E	5-year percentile	P/S	EV/Sales	EV/EBITDA
Dec 29, 2025	31.8×	95	9.9×	9.4×	26.3×
Dec 30, 2024	n/m	Too little history	10.0×	9.4×	n/m
Dec 25, 2023	30.6×	82	11.0×	9.8×	23.3×
Dec 26, 2022	22.8×	27	8.6×	7.5×	15.2×
Dec 27, 2021	26.4×	40	8.0×	7.0×	18.1×
Dec 28, 2020	23.1×	22	10.4×	9.4×	20.3×
Dec 30, 2019	26.4×	29	15.7×	14.6×	60.4×
Dec 31, 2018	69.1×	8	15.9×	14.8×	59.5×
Dec 25, 2017	192.1×	92	16.3×	15.6×	365.9×
Dec 26, 2016	n/m	Too little history	10.9×	10.2×	n/m

Health Care peers on P/E

Each percentile compares a stock with its own last five years.

Compare VRTX with peers

Health Care peers of VRTX on P/E
Stock	P/E	Versus its own history	5-year percentile
ABBVAbbVie	80.8×	Above its usual range	76
AMGNAmgen	28.1×	Above its usual range	80
ARWRArrowhead Pharmaceuticals Inc	n/m	Not ranked	n/m, not ranked
BBIOBridgebio Pharma Inc	n/m	Not ranked	n/m, not ranked
BIIBBiogen	105.2×	Historically high	100

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on VRTX

No articles about VRTX yet. How valuation percentiles work

Loading peers and related research…

About this history

What is VRTX's current P/E?: Vertex Pharmaceuticals' P/E of 30.9x is higher than 83% of its weekly readings over the last five years (as of Oct 29, 2026).
What is VRTX's five-year median P/E?: 28.1x. Half of VRTX's weekly readings over the last five years were higher and half were lower. This page has 820 weekly readings, from Feb 14, 2011 to Oct 26, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares VRTX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.